JP2017176174A5 - - Google Patents

Download PDF

Info

Publication number
JP2017176174A5
JP2017176174A5 JP2017057024A JP2017057024A JP2017176174A5 JP 2017176174 A5 JP2017176174 A5 JP 2017176174A5 JP 2017057024 A JP2017057024 A JP 2017057024A JP 2017057024 A JP2017057024 A JP 2017057024A JP 2017176174 A5 JP2017176174 A5 JP 2017176174A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
region
same amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017057024A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017176174A (ja
JP6392923B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017176174A publication Critical patent/JP2017176174A/ja
Publication of JP2017176174A5 publication Critical patent/JP2017176174A5/ja
Application granted granted Critical
Publication of JP6392923B2 publication Critical patent/JP6392923B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017057024A 2008-10-06 2017-03-23 Ｍｕｃ１＊抗体 Active JP6392923B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10320408P 2008-10-06 2008-10-06
US61/103,204 2008-10-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014226709A Division JP6230983B2 (ja) 2008-10-06 2014-11-07 Ｍｕｃ１＊抗体

Publications (3)

Publication Number Publication Date
JP2017176174A JP2017176174A (ja) 2017-10-05
JP2017176174A5 true JP2017176174A5 (enExample) 2017-11-16
JP6392923B2 JP6392923B2 (ja) 2018-09-19

Family

ID=42101177

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011531128A Pending JP2012504961A (ja) 2008-10-06 2009-10-06 Ｍｕｃ１＊抗体
JP2014226709A Active JP6230983B2 (ja) 2008-10-06 2014-11-07 Ｍｕｃ１＊抗体
JP2017057024A Active JP6392923B2 (ja) 2008-10-06 2017-03-23 Ｍｕｃ１＊抗体

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2011531128A Pending JP2012504961A (ja) 2008-10-06 2009-10-06 Ｍｕｃ１＊抗体
JP2014226709A Active JP6230983B2 (ja) 2008-10-06 2014-11-07 Ｍｕｃ１＊抗体

Country Status (8)

Country Link
US (4) US10421819B2 (enExample)
EP (3) EP4083072A1 (enExample)
JP (3) JP2012504961A (enExample)
KR (1) KR101455447B1 (enExample)
CN (1) CN102239182B (enExample)
CR (1) CR20110238A (enExample)
IL (1) IL212175B (enExample)
WO (1) WO2010042562A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102239182B (zh) 2008-10-06 2014-07-09 米纳瓦生物技术公司 Muc1*抗体
KR20140101876A (ko) * 2008-10-09 2014-08-20 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
US8518405B2 (en) * 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
US20120156246A1 (en) * 2010-06-16 2012-06-21 Bamdad Cynthia C Reprogramming cancer cells
EP2407487A1 (en) * 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
EP4086338A1 (en) * 2011-03-17 2022-11-09 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
CN102716472A (zh) * 2011-03-31 2012-10-10 李光辉 一种肿瘤疫苗及其合成方法
JP6748430B2 (ja) * 2012-07-13 2020-09-02 ミネルバ バイオテクノロジーズ コーポレーション より未分化状態への細胞の誘導方法
CN104717980A (zh) * 2012-08-14 2015-06-17 米纳瓦生物技术公司 干细胞增强疗法
CA2886161A1 (en) * 2012-09-29 2014-04-03 The Trustees Of The University Of Pennsylvania Veterinary composition and methods for non-surgical neutering and castration
CN103848890B (zh) * 2012-11-30 2015-09-09 北京市结核病胸部肿瘤研究所 Muc1自身抗体识别的抗原多肽
CA2898239A1 (en) 2013-01-23 2014-07-31 Syddansk Universitet Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors
MX380864B (es) 2014-01-29 2025-03-12 Dana Farber Cancer Inst Inc Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd).
CN103880956B (zh) * 2014-03-10 2015-12-30 中国人民解放军第四军医大学 抗muc1单克隆抗体及其轻链和重链可变区
EP4050103A1 (en) 2014-04-07 2022-08-31 Minerva Biotechnologies Corporation Anti-nme antibody
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
WO2016042412A1 (en) * 2014-09-16 2016-03-24 Symphogen A/S Anti-met antibodies and compositions
KR102390359B1 (ko) * 2014-09-29 2022-04-22 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
KR20170063881A (ko) 2014-10-02 2017-06-08 시티 오브 호프 다가 메디토프, 메디토프 결합 항체 및 이의 용도
US9688750B2 (en) 2014-10-07 2017-06-27 Ann And Robert H. Lurie Children's Hospital Of Chicago Anti-nodal antibodies and methods of using same
JP6895890B2 (ja) * 2015-02-10 2021-06-30 ミネルバ バイオテクノロジーズ コーポレーション ヒト化抗ｍｕｃ１＊ 抗体
MX2018006973A (es) * 2015-12-09 2019-05-16 Corvus Pharmaceuticals Inc Anticuerpos anti-cd73 humanizados.
EP4245775A3 (en) * 2016-04-29 2023-11-15 Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. Multi-specific binding conjugate, related pharmaceutical compositions and use
CA3050039A1 (en) * 2017-01-27 2018-08-02 Glycotope Gmbh Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
SG11201908813QA (en) * 2017-04-13 2019-10-30 Aduro Biotech Holdings Europe B V Anti-sirp alpha antibodies
CN109971713B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 稳定表达PD-1抗体的Muc1特异性CAR-T细胞及其用途
KR20200118151A (ko) * 2018-02-07 2020-10-14 리제너론 파마슈티칼스 인코포레이티드 치료 단백질 전달을 위한 방법 및 조성물
US20200405832A1 (en) * 2018-03-09 2020-12-31 Minerva Biotechnologies Corporation Method for anti-muc1* car t cell stimulation
CN120484122A (zh) * 2019-01-11 2025-08-15 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
CN113727602B (zh) 2019-02-04 2023-10-03 米纳瓦生物技术公司 抗nme抗体及治疗癌症或癌症转移的方法
IL298780A (en) 2020-06-08 2023-02-01 Minerva Biotechnologies Corp Anti-nme antibody and method of treating cancer or cancer metastasis
CN116075318A (zh) 2020-06-26 2023-05-05 米纳瓦生物技术公司 抗nme抗体及治疗癌症或癌症转移的方法
MX2023000784A (es) * 2020-07-16 2023-04-18 Dana Farber Cancer Inst Inc Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd).
US11970546B2 (en) * 2020-07-31 2024-04-30 R.P. Scherer Technologies, Llc Antibody specific for Mucin-1 and methods of use thereof
WO2023201234A2 (en) 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof
EP4646444A1 (en) * 2023-01-04 2025-11-12 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-muc1 antibodies and uses thereof
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases
US20250121088A1 (en) 2023-10-11 2025-04-17 Minerva Biotechnologies Corporation Anti-muc1* antibody drug complexes and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US20020136725A1 (en) 1996-01-17 2002-09-26 Smithkline Beecham Corporation Antithrombotic agents
TWI242563B (en) * 1998-04-30 2005-11-01 Tanox Inc Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor
EP1131106B1 (en) * 1998-11-12 2009-06-24 Novolytics Inc. Compositions and methods for producing vascular occlusion
US20020064528A1 (en) * 2000-01-28 2002-05-30 Zhenping Zhu Antibodies specific to KDR and uses thereof
US20020052311A1 (en) * 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
AU4976001A (en) * 2000-03-30 2001-10-15 Dyax Corp Mucin-1 specific binding members and methods of use thereof
EP1300159B1 (en) 2000-06-29 2007-10-10 Anthera Pharmaceuticals, Inc. Remedies for cancer
EP1317278B1 (en) 2000-09-11 2009-11-11 Dana-Farber Cancer Institute, Inc. Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
JP4564714B2 (ja) * 2000-11-27 2010-10-20 ミナーヴァ・バイオテクノロジーズ・コーポレーション 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法
JP2005508839A (ja) * 2001-03-29 2005-04-07 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド ペプチドおよびｍｕｃ１タンパク質に対する抗体
US7630836B2 (en) 2001-05-30 2009-12-08 The Kitasato Institute Polynucleotides
EP2329822A1 (en) 2001-09-05 2011-06-08 Minerva Biotechnologies Corporation Compositions and methods of treatment of cancer
ES2871905T3 (es) * 2002-03-01 2021-11-02 Immunomedics Inc Inmunoconjugado que comprende anticuerpos de RS7 humanizados
JP2006504630A (ja) * 2002-04-22 2006-02-09 ダイアックス コーポレイション ムチンポリペプチドに特異的な抗体
EP1519958B1 (en) * 2002-06-14 2014-10-15 Immunomedics, Inc. Humanized monoclonal antibody hpam4
CA2537263C (en) 2002-11-27 2017-05-30 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US20060173171A1 (en) 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
EP1716181B1 (en) 2004-02-19 2009-12-16 Genentech, Inc. Cdr-repaired antibodies
AU2005294146B2 (en) * 2004-10-04 2011-09-15 Genentech, Inc. Modulators of hepatocyte growth factor activator
EP2526957A3 (en) * 2005-03-30 2013-02-20 Minerva Biotechnologies Corporation Proliferation of MUC1 expressing cells
US20090075926A1 (en) 2006-12-06 2009-03-19 Bamdad Cynthia C Method for identifying and manipulating cells
US8420591B2 (en) * 2006-12-08 2013-04-16 Dana-Farber Cancer Institute, Inc. MUC1 and galectin-3
CN102239182B (zh) 2008-10-06 2014-07-09 米纳瓦生物技术公司 Muc1*抗体
CN104717980A (zh) * 2012-08-14 2015-06-17 米纳瓦生物技术公司 干细胞增强疗法
JP6895890B2 (ja) * 2015-02-10 2021-06-30 ミネルバ バイオテクノロジーズ コーポレーション ヒト化抗ｍｕｃ１＊ 抗体

Similar Documents

Publication Publication Date Title
JP2017176174A5 (enExample)
JP2018504907A5 (enExample)
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
JP2019524645A5 (enExample)
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
JP2014205674A5 (enExample)
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
JP2016185981A5 (enExample)
WO2016207304A8 (en) Monoclonal anti-il-1racp antibodies
JP2019528240A5 (enExample)
CN113316591A (zh) Cd73抗体及其制备方法和应用
NZ743713A (en) Human immunodeficiency virus neutralizing antibodies
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
CN110291109A (zh) 人程序性死亡受体pd-1的单克隆抗体及其片段
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
JP2013539454A5 (enExample)
AR105267A1 (es) Anticuerpos de unión a tau
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses
PE20190737A1 (es) Anticuerpos anti-cd27
JP2018537399A5 (enExample)
WO2012047732A3 (en) Antibody compositions and methods of use